Less medication switching after initial start with atypical antipsychotics

European Neuropsychopharmacology

Volumn 14, Issue 1, 2004, Pages 1-5

  Hugenholtz, Gerard W K ^a,b   Heerdink, Eibert R ^b   Nolen, Willem A ^a,c   Egberts, Antoine C G ^b  

^a Altrecht Institute for Mental Health Care   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Antipsychotic; Epidemiology; Pharmacoepidemiology; Switch

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; BROMPERIDOL; CLOZAPINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PENFLURIDOL; PERPHENAZINE; PIMOZIDE; RISPERIDONE; SERTINDOLE; ZUCLOPENTHIXOL;

ADOLESCENT; ADULT; ANXIETY DISORDER; ARTICLE; BIPOLAR DISORDER; CASE CONTROL STUDY; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CONTROLLED STUDY; DEPRESSION; FEMALE; FOLLOW UP; HOSPITAL PATIENT; HUMAN; KAPLAN MEIER METHOD; LOGISTIC REGRESSION ANALYSIS; MALE; MENTAL DISEASE; MENTAL PATIENT; ORAL DRUG ADMINISTRATION; PERSONALITY DISORDER; PHARMACOEPIDEMIOLOGY; PRIORITY JOURNAL; PSYCHOLOGICAL ASPECT; PSYCHOSIS; RETROSPECTIVE STUDY; RISK; STATISTICAL MODEL; SURVIVAL; TREATMENT OUTCOME;

EID: 0345118053     PISSN: 0924977X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-977X(03)00043-9     Document Type: Article

References (25)

1. Anonymous, 1994, Diagnostic and Statistical Manual for Mental Disorders, 4th Edition, DSM-IV, American Psychiatric Association, Washington, DC.
2. Anonymous, 1997, Practice guideline for the treatment of patients with schizophrenia. American Psychiatric Association, Am. J. Psychiatry 154, 1.
3. Anonymous, 2000, Anatomical Therapeutical Chemical (ATC) Classification Index, WHO Collaboration Centre for Drugs Statistics Methodology, Oslo.
4. Davis J.M., Janicak P.G., Wang Z., Gibbons R.D., Sharma R.P. The efficacy of psychotropic drugs: implications for power analysis. Psychopharmacol. Bull. 28:1992;151.
5. Duggan L., Fenton M., Dardennes R.M., El-Dosoky A., Indran S. Olanzapine for schizophrenia (Cochrane Review). The Library, Issue 1. 2003;Update Software, Oxford.
6. Geddes J., Freemantle N., Harrison P., Bebbington P. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. Br. Med. J. 321:2000;1371.
7. Herings R.M., Bakker A., Stricker B.H., Nap G. Pharmaco-morbidity linkage: a feasibility study comparing morbidity in two pharmacy based exposure cohorts. J. Epidemiol. Community Health. 46:1992;136.
8. Hugenholtz G.W.K., Heerdink E.R., Nolen W.A., Leufkens H.G.M. [Antipsychotics in newly admitted psychiatric patients: the choice between typical and atypical]. Pharm. Weekblad. 137:2002;738.
9. Kennedy E., Song F., Hunter R., Clarke A., Gilbody S. Risperidone versus typical antipsychotic medication for schizophrenia (Cochrane Review). The Cochrane Library, Issue 1. 2003;Update Software, Oxford.
10. Kinon B.J., Lieberman J.A. Mechanisms of action of atypical antipsychotic drugs: a critical analysis. Psychopharmacology (Berl.). 124:1996;2.
11. Leslie D.L., Rosenheck R.A. From conventional to atypical antipsychotics and back: dynamic processes in the diffusion of new medications. Am. J. Psychiatry. 159:2002;1534.
12. Leucht S., Pitschel-Walz G., Abraham D., Kissling W. Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. Schizophr. Res. 35:1999;51.
13. Lieberman J.A., Saltz B.L., Johns C.A., Pollack S., Borenstein M., Kane J. The effects of clozapine on tardive dyskinesia. Br. J. Psychiatry. 158:1991;503.
14. Meltzer H.Y. Outcome in schizophrenia: beyond symptom reduction. J. Clin. Psychiatry. 60:(Suppl. 3):1999;3.
15. Meyer J.M. A retrospective comparison of weight, lipid, and glucose changes between risperidone- and olanzapine-treated inpatients: metabolic outcomes after 1 year. J. Clin. Psychiatry. 63:2002;425.
16. Moller H.J. Novel antipsychotics and negative symptoms. Int. Clin. Psychopharmacol. 13:(Suppl. 3):1998;S43.
17. Newcomer J.W., Haupt D.W., Fucetola R., Melson A.K., Schweiger J.A., Cooper B.P., Selke G. Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia. Arch. Gen. Psychiatry. 59:2002;337.
18. Owens D.G. Adverse effects of antipsychotic agents. Do newer agents offer advantages? Drugs. 51:1996;895.
19. Sarfati Y., Olivier V., Bouhassira M. [New antipsychotics in the treatment of schizophrenia A European survey]. Encephale. 25:1999;658.
20. Srisurapanont M., Disayavanish C., Taimkaew K. Quetiapine for schizophrenia (Cochrane Review). The Cochrane Library, Issue 1. 2003;Update Software, Oxford.
21. Tuunainen A., Wahlbeck K., Gilbody S.M. Newer atypical antipsychotic medication versus clozapine for schizophrenia (Cochrane Review). The Cochrane Library, Issue 1. 2003;Update Software, Oxford.
22. Wahlbeck K., Cheine M., Tuisku K., Ahokas A., Joffe G., Rimon R. Risperidone versus clozapine in treatment-resistant schizophrenia: a randomized pilot study. Prog. Neuropsychopharmacol. Biol. Psychiatry. 24:2000;911.
23. Wahlbeck K., Cheine M., Essali M.A. Clozapine versus typical neuroleptic medication for schizophrenia (Cochrane Review). The Cochrane Library, Issue 1. 2003;Update Software, Oxford.
24. Weiden P.J., Aquila R., Dalheim L., Standard J.M. Switching antipsychotic medications. J. Clin. Psychiatry. 58:1997;63.
25. Williams C.L., Johnstone B.M., Kesterson J.G., Javor K.A., Schmetzer A.D. Evaluation of antipsychotic and concomitant medication use patterns in patients with schizophrenia. Med. Care. 37:1999;AS81.